Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Backgruound: Despite the protective effects of stromal cell-derived factor 1 (SDF-1) in stimulating muscle regeneration shown in experimental research, there is a lack of clinical studies linking circulating SDF-1 concentrations with muscle phenotypes. In order to elucidate the role of SDF-1 as a potential biomarker reflecting human muscle health, we investigated the association of plasma SDF-1 levels with sarcopenia in older adults.
Methods: This cross-sectional study included 97 community-dwelling participants who underwent a comprehensive geriatric assessment at a tertiary hospital in South Korea. Sarcopenia was defined by specific cutoff values applicable to the Asian population, whereas plasma SDF-1 levels were determined using an enzyme immunoassay.
Results: After accounting for sex, age, and body mass index, participants with sarcopenia and low muscle mass exhibited plasma SDF-1 levels that were 21.8% and 18.3% lower than those without these conditions, respectively (P=0.008 and P=0.009, respectively). Consistently, higher plasma SDF-1 levels exhibited a significant correlation with higher skeletal muscle mass index (SMI) and gait speed (both P=0.043), and the risk of sarcopenia and low muscle mass decreased by 58% and 55% per standard deviation increase in plasma SDF-1 levels, respectively (P=0.045 and P=0.030, respectively). Furthermore, participants in the highest SDF-1 tertile exhibited significantly higher SMI compared to those in the lowest tertile (P=0.012).
Conclusion: These findings clinically corroborate earlier experimental discoveries highlighting the muscle anabolic effects of SDF- 1 and support the potential role of circulating SDF-1 as a biomarker reflecting human muscle health in older adults.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764998 | PMC |
| http://dx.doi.org/10.3803/EnM.2023.1783 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined comprehensive treatment for hepatocellular carcinoma.
Ann Hepatol
August 2025
Department of Hepatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address:
Introduction And Objectives: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with intra-arterial bevacizumab infusion in patients with advanced hepatocellular carcinoma (HCC).
Patients And Methods: In this prospective randomized controlled trial, 120 patients with advanced HCC (stages Ib-IIIb) were enrolled between March 2021 and October 2023 and randomized to receive TACE alone (control group, n = 60) or TACE plus intra-arterial bevacizumab (combined group, n = 60). Tumor perfusion parameters were assessed via dynamic contrast-enhanced MRI (DCE-MRI), while VEGF and SDF-1 levels were measured using ELISA.
Amyloid-β-driven Alzheimer's disease reshapes the colonic immune system in mice.
Cell Rep
August 2025
Department of Immunology, University of Toronto, Toronto, ON, Canada; Buck Institute for Research in Aging, Novato, CA, USA; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA; Division of Cellular & Molecular Biology, Toronto General Hospital Research Insti
The "gut-brain axis" is an emerging target in Alzheimer's disease (AD), although its immunological features remain poorly understood. Using single-cell RNA sequencing, coupled to extensive spectral-tuning flow cytometry validation of the colon immune compartment in the 5XFAD amyloid-β mouse model, we found several AD-associated changes including in B/plasma cell activity. Notably, levels of CXCR4 antibody-secreting cells are reduced in 5XFAD colons.
View Article and Find Full Text PDFPlasma levels of the lymphangiogenic factors VEGF-C, VEGF-D, and CXCL-12 are elevated in advanced diabetic nephropathy.
Ren Fail
December 2025
Department of Cardiology, The 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Objective: Early biomarkers for diabetic nephropathy progression remain limited. This study aims to investigate whether plasma levels of VEGF-C, VEGF-D, and CXCL-12 can reflect the severity of diabetic kidney disease (DKD), and to evaluate their potential as biomarkers for disease monitoring.
Methods: Patients were divided into normal albuminuria group (UmAlb < 30 mg/24 h, = 30), microalbuminuria group (UmAlb 30-300 mg/24 h, = 30) and macroalbuminuria group (UmAlb >300 mg/24 h, = 30).
CXCL12/CXCR4 modulates macrophage efferocytosis to induce glomerular crescent formation and fibrosis via ELMO1/DOCK180/RAC1 signaling in ANCA-associated glomerulonephritis.
Cell Mol Life Sci
July 2025
Department of Nephrology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Children's Hospital of Chongqing Medical University, Chongq
Background: ANCA-associated glomerulonephritis (AAGN) is a leading cause of uremia in children, driven by macrophages (Mφs) that mediate crescent formation and fibrosis. Despite their critical role, the signals governing monocyte recruitment and macrophage polarization in AAGN remain unclear.
Methods: We utilized single-cell sequencing to dissect the cellular dynamics of AAGN and conducted in vitro and in vivo experiments to explore the role of the CXCL12/CXCR4 signaling axis in monocyte recruitment and macrophage efferocytosis.
Tissue factor pathway inhibitor promotes the migration, proliferation and colonization of MSCs by regulating CXCL12/CXCR4 signaling pathway.
Biochem Biophys Res Commun
September 2025
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Electronic address:
MSCs (mesenchymal stem cells) can promote the structural and functional recovery of lung injury, but most of MSCs do not retain in the injury sites. TFPI (tissue factor pathway inhibitors) can promote stem/progenitor cell migration and homing. The objective of this study was to clarify the feasibility and efficacy of TFPI combined with MSCs in alleviating lung injury and explore the possible mechanism.
View Article and Find Full Text PDF